Inhalable resveratrol microparticles produced by vibrational atomization spray drying for treating pulmonary arterial hypertension

被引:28
|
作者
Dimer, Frantiescoli A. [1 ]
Ortiz, Manoel [1 ]
Pohlmann, Adriana R. [1 ,2 ,3 ]
Guterres, Silvia S. [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Fac Farm, BR-90610000 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Dept Quim Orgen, Inst Quim, BR-90610000 Porto Alegre, RS, Brazil
[3] Univ Fed Rio Grande do Sul, Programa Posgrad Quim, Inst Quim, BR-90610000 Porto Alegre, RS, Brazil
关键词
Dry powder inhaler; Pulmonary arterial hypertension; Resveratrol; Spray dryer; Vibrational atomization; DRUG-DELIVERY SYSTEMS; POLYMERIC PARTICLES; NANOPARTICLES; RELEASE; SURFACE; MICROSPHERES; NANOCAPSULES; RATS;
D O I
10.1016/j.jddst.2015.07.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The rare disorder pulmonary arterial hypertension is characterized by elevated pulmonary arterial pressure and right heart failure. Currently, the treatments have improved, but a cure has not yet been discovered. In this study, we developed a new formulation using an innovative controlled delivery system for resveratrol: s dry powder inhaler form designed for pulmonary administration. The particles were composed of resveratrol, as the therapeutic agent; poly(e-caprolactone), for structuring the controlled-release matrix; sodium deoxycholate, to prevent agglomeration; and trehalose, as drying adjuvant, respectively. The particles were obtained using the piezoelectric atomization technique with a Nano Spray Dryer B-90 (R). The fine particle fraction was approximately 50% and the theoretical aerodynamic diameter was 232 mu m. The process afforded excellent yields (approximately 80%) with low powder moisture (less than 2.0%). Due to the low density and the increased flowability of the powder, the spherical shape of the particles and an irregular surface, the microparticles possessed aerodynamic properties suitable for drug deposition on the bronchial and alveolar regions of the lungs. The aerodynamic properties and in vitro sustained release profiles showed a great potential for the inhaled administration of drugs such as resveratrol suitable for the treatment of pulmonary arterial hypertension. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 46 条
  • [31] Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
    Xiao, Lianghua
    Feng, Xinwei
    Zhang, Huahua
    Zhong, Lin
    Song, Xiaobing
    Wang, Fangfang
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2024, 20 (03): : 258 - 263
  • [32] Inhalable spray-dried porous microparticles containing dehydroandrographolide succinate phospholipid complex capable of improving and prolonging pulmonary anti-inflammatory efficacy in mice
    Chen, Wei-Ya
    Wei, Jia-Xing
    Yu, Chen-Yang
    Liu, Chun-Yu
    Liao, Yong-Hong
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2025, 15 (02) : 670 - 687
  • [33] Circulating microparticles in severe pulmonary arterial hypertension increase intercellular adhesion molecule-1 expression selectively in pulmonary artery endothelium
    Blair, Leslie A.
    Haven, April K.
    Bauer, Natalie N.
    RESPIRATORY RESEARCH, 2016, 17
  • [34] Adipose-derived stem cell transplantation in treating monocrotaline-induced pulmonary arterial hypertension
    Qin, Youzhen
    Tang, Mingsheng
    Wang, Huishen
    Li, Yunquan
    Li, Shujuan
    Lin, Yuese
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (07): : 2903 - 2908
  • [35] Efficacy and Safety of Treating Pulmonary Arterial Hypertension With Imatinib: A Meta-Analysis of Randomized Controlled Trials
    Chen, Xiaofa
    Xue, Bijuan
    Xu, Lina
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2025, 85 (03) : 177 - 185
  • [36] Development of Budesonide Microparticles Using Spray-Drying Technology for Pulmonary Administration: Design, Characterization, In Vitro Evaluation, and In Vivo Efficacy Study
    Sonali R. Naikwade
    Amrita N. Bajaj
    Prashant Gurav
    Madhumanjiri M. Gatne
    Pritam Singh Soni
    AAPS PharmSciTech, 2009, 10 : 993 - 1012
  • [37] Development of Budesonide Microparticles Using Spray-Drying Technology for Pulmonary Administration: Design, Characterization, In Vitro Evaluation, and In Vivo Efficacy Study
    Naikwade, Sonali R.
    Bajaj, Amrita N.
    Gurav, Prashant
    Gatne, Madhumanjiri M.
    Soni, Pritam Singh
    AAPS PHARMSCITECH, 2009, 10 (03): : 993 - 1012
  • [38] Screening and treating pulmonary arterial hypertension in a tertiary hospital-based multidisciplinary clinic: the first 200 patients
    Low, A. J.
    Fowler, D.
    Manghani, M. K.
    Young, I.
    Garsia, R.
    Torzillo, P.
    Youssef, P.
    Celermajer, D. S.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 32 - 37
  • [39] Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (07) : 589 - 593
  • [40] A New Class of Drug for Pulmonary Arterial Hypertension - Can a Rho-Kinase Inhibitor Break the Stagnation in Treating It?
    Miyagawa, Kazuya
    Emoto, Noriaki
    CIRCULATION JOURNAL, 2013, 77 (10) : 2477 - 2478